Myelogenous Leukemia

Oncology·MeSH: Leukemia, Myeloid

Prevalence

30.0 / 100K

61 drugs in development·19 companies·1 clinical trial

Drug Pipeline by Phase

Approved(4)

Drug	Company
bosutinib	SUNSET ISLAND GROUP (SUN)
bosutinib	Impax Laboratories, LLC (IPXL)
busulfan	Amneal Pharmaceuticals, Inc. (AMRX)
busulfan	NEXUS BIOPHARMA INC (NEXS)

Phase 3(19)

Drug	Company
abl001 200mg qd	Novartis AG (NVS)
abl001 200mg qd	NOVARTIS AG (NVSEF)
abl001 40mg bid	NOVARTIS AG (NVSEF)
abl001 40mg bid	Novartis AG (NVS)
abl001 80mg qd	Novartis AG (NVS)
abl001 80mg qd	NOVARTIS AG (NVSEF)
asciminib single agent	NOVARTIS AG (NVSEF)
Blinatumomab	Assertio Holdings, Inc. (ASRT)
bosutinib	Novartis AG (NVS)
bosutinib	GH Research PLC (GHRS)
Cytarabine	Assertio Holdings, Inc. (ASRT)
Filgrastim	Assertio Holdings, Inc. (ASRT)
imatinib	GH Research PLC (GHRS)
Liposome-encapsulated Daunorubicin-Cytarabine	Assertio Holdings, Inc. (ASRT)
MCLA-158 (petosemtamab)	Merus N.V. (MRUS)
nilotinib	GH Research PLC (GHRS)
Petosemtamab (MCLA-158)	Merus N.V. (MRUS)
Ponatinib	ENANTA PHARMACEUTICALS INC (ENTA)
Vincristine	Assertio Holdings, Inc. (ASRT)

Phase 2(22)

Drug	Company
ABT-199	AbbVie Inc. (ABBV)
asciminib single agent	Novartis AG (NVS)
conditioning regimen a	HWH International Inc. (HWH)
conditioning regimen b	HWH International Inc. (HWH)
conditioning regimen c	HWH International Inc. (HWH)
conditioning regimen d	HWH International Inc. (HWH)
conditioning regimen e	HWH International Inc. (HWH)
Cytarabine	AbbVie Inc. (ABBV)
Emavusertib (CA-4948)	CURIS INC (CRIS)
Glasdegib	Jazz Pharmaceuticals plc (JAZZ)
imatinib	Novartis AG (NVS)
MCLA-145	Merus N.V. (MRUS)
Pegfilgrastim	Assertio Holdings, Inc. (ASRT)
Ponatinib	Assertio Holdings, Inc. (ASRT)
post-transplant abatacept	HWH International Inc. (HWH)
post-transplant mycophenolate mofetil	HWH International Inc. (HWH)
post-transplant tacrolimus	HWH International Inc. (HWH)
ptcy (25 mg/kg d3	HWH International Inc. (HWH)
ptcy (25 mg/kg d3	GH Research PLC (GHRS)
ptcy (50 mg/kg d3	HWH International Inc. (HWH)
ptcy (50 mg/kg d3	GH Research PLC (GHRS)
supportive care	HWH International Inc. (HWH)

Phase 1(7)

Drug	Company
Cytarabine	Structure Therapeutics Inc. (GPCR)
elvn-001	Enliven Therapeutics, Inc. (ELVN)
emavusertib	CURIS INC (CRIS)
MCLA-117 bispecific antibody	Merus N.V. (MRUS)
mipletamig	Aptevo Therapeutics Inc. (APVO)
Posaconazole	AbbVie Inc. (ABBV)
Vincristine	Structure Therapeutics Inc. (GPCR)

Preclinical(1)

Drug	Company
gtb-3550	GT Biopharma, Inc. (GTBP)

N/A(1)

Drug	Company
LILRB4 STAR-T cells injection	Filana Therapeutics Inc. (FLNA)

Phase 1/Phase 2(2)

Drug	Company
cd33cart allogeneic	HWH International Inc. (HWH)
cd33cart autologous	HWH International Inc. (HWH)

Phase 4(5)

Drug	Company
asciminib single agent pediatric formulation	Novartis AG (NVS)
asciminib single agent pediatric formulation	NOVARTIS AG (NVSEF)
bosutinib	Novartis AG (NVS)
imatinib	Novartis AG (NVS)
Infusion of HS-IT101 Injection	Filana Therapeutics Inc. (FLNA)

BioSniper tracks 61 drugs in development for Myelogenous Leukemia across 19 companies.

There are 1 clinical trial targeting Myelogenous Leukemia tracked by BioSniper.

The estimated prevalence of Myelogenous Leukemia is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.